Brentuximab Vedotin
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly
Explore 24 assets in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Modality
antibody_drug_conjugate
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06925555CT.gov Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | The First Affiliated Hospital with Nanjing Medical University | P2 | CCC · 53 |
| Adriamycin | University of Washington | P2/3 | BB |
| Prednisone | University of Washington | P2/3 | BB |
| Cyclophosphamide | University of Washington | P2/3 | BB |
| Rituximab | University of Washington | P2/3 | BB |
| Etoposide | University of Washington | P2/3 | B |
| Vincristine Sulfate | Northwestern University | P2/3 | B |
| (+)-Vincristine | Patrick C. Johnson, MD | P2 | B |
| Azacitidine | National Cancer Institute (NCI) | P2/3 | CCC |
+22 more in the Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-of-the-elderly
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →